Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2-Reference-Cited by-同舟云学术

Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2

Published:2023-10-09 Issue:19 Volume:8 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Horton Brendan L.,D’Souza Alicia D.,Zagorulya Maria^ORCID,McCreery Chloe V.,Abhiraman Gita C.,Picton Lora,Sheen Allison,Agarwal Yash,Momin Noor,Wittrup K. Dane,White Forest M.,Garcia K. Christopher^ORCID,Spranger Stefani

Funder

Pew Charitable Trusts

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/172728/files/pdf

Reference46 articles.

1. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

3. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

4. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

5. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing non-small cell lung cancer treatment: the power of combination immunotherapies;Frontiers in Immunology;2024-07-02

2. Identification of key genes and biological pathways in chronic obstructive pulmonary disease using bioinformatics and next generation sequencing data analysis;2024-02-14